BrainsWay to Report Second Quarter Financial Results on August 10, 2022

Rhea-AI Summary

Burlington, Mass. and Jerusalem, July 27, 2022 - BrainsWay Ltd. (BWAY) will report its second quarter financial results before U.S. markets open on August 10, 2022. A conference call will follow at 8:30 AM ET to discuss these results and update on business operations. BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, with FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. For further details and to access the call, visit their official website.

Positive

• BrainsWay is the first TMS company with three FDA-cleared indications.
• Proprietary Deep TMS™ platform technology is clinically proven for various mental health disorders.

Negative

• None.

BURLINGTON, Mass. and JERUSALEM, July 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 10, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, August 10, 2022
Time:	8:30 AM Eastern Time
United States:	877-407-3982
International:	201-493-6780
Conference ID:	13731331
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1558822&tp_key=74e2e8e62b

The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts: 
BrainsWay:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
SAreglado@brainsway.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

When will BrainsWay report its second quarter financial results?

BrainsWay will report its second quarter financial results on August 10, 2022.

What time is the BrainsWay conference call on August 10, 2022?

The BrainsWay conference call is scheduled for 8:30 AM Eastern Time.

What is the purpose of BrainsWay's conference call?

The conference call will discuss financial results and provide updates on business operations.

What are the FDA-cleared indications for BrainsWay's TMS technology?

BrainsWay's TMS technology is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

How can I access the BrainsWay conference call?

You can access the conference call via their website or by calling the provided numbers.